William Blair Investment Management LLC lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 10.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 645,130 shares of the company’s stock after buying an additional 62,178 shares during the period. William Blair Investment Management LLC’s holdings in Progyny were worth $16,251,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the company. Bank of America Corp DE purchased a new stake in Progyny in the second quarter worth approximately $17,264,000. Hsbc Holdings PLC bought a new position in Progyny during the second quarter valued at approximately $760,000. AWM Investment Company Inc. bought a new position in Progyny during the second quarter valued at approximately $6,343,000. Corient Private Wealth LP purchased a new position in shares of Progyny during the second quarter worth approximately $3,488,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Progyny during the second quarter worth approximately $1,705,000. Institutional investors own 94.93% of the company’s stock.
Insider Transactions at Progyny
In related news, Chairman David Schlanger sold 161,208 shares of Progyny stock in a transaction on Monday, November 9th. The shares were sold at an average price of $35.73, for a total value of $5,759,961.84. Following the transaction, the chairman directly owned 238,462 shares of the company’s stock, valued at $8,520,247.26. The trade was a 40.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the transaction, the executive vice president directly owned 75,816 shares in the company, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 630,072 shares of company stock valued at $22,363,084. 9.90% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on PGNY. BTIG Research boosted their price objective on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Jefferies Financial Group set a $33.00 target price on shares of Progyny in a report on Tuesday, September 8th. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Monday, October 19th. Barclays decreased their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a research note on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.33.
View Our Latest Stock Report on Progyny
Progyny Price Performance
Shares of PGNY stock opened at $36.18 on Monday. The stock has a market capitalization of $2.66 billion, a PE ratio of 33.19, a P/E/G ratio of 1.66 and a beta of 0.97. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $37.15. The business has a 50-day moving average of $28.48 and a 200 day moving average of $24.87.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. The business had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 19.82% and a net margin of 6.80%. Progyny’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $0.15 EPS. Analysts anticipate that Progyny, Inc. will post 1.43 EPS for the current year.
Progyny Profile
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Featured Stories
- Five stocks we like better than Progyny
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
